From concept through commercialization:
RVL meets patient needs.

RVL Pipeline: A Look Ahead

RVL Pharmaceuticals is actively evaluating label expansion opportunities for Upneeq^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. A second-generation formulation of Upneeq is currently under development.